Stagnant health technologies in Africa

Science

Volumn 330, Issue 6010, 2010, Pages 1483-1484

  Simiyu, Ken ^a   Daar, Abdallah S ^a   Singer, Peter A ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISIN; MONOCLONAL ANTIBODY;

COMMERCIALIZATION; DISEASE CONTROL; DISEASE PREVALENCE; ECONOMIC ANALYSIS; EPIDEMIOLOGY; HEALTH POLICY; HEALTH RISK; TECHNOLOGICAL DEVELOPMENT;

AFRICA; ARTEMISIA ANNUA; COMMERCIAL PHENOMENA; COST BENEFIT ANALYSIS; CRYPTOLEPIS; DIAGNOSTIC TEST; DRUG RESISTANT TUBERCULOSIS; HEALTH TECHNOLOGY; INCINERATION; MEDICAL INSTRUMENTATION; MEDICAL RESEARCH; PLASMODIUM; PRIORITY JOURNAL; REVIEW; TECHNOLOGY; TRADITIONAL MEDICINE; AFRICA SOUTH OF THE SAHARA; ARTICLE; ECONOMICS; HEALTH; HUMAN; INVESTMENT; MARKETING; MASS COMMUNICATION; MEDICAL TECHNOLOGY; PUBLIC-PRIVATE PARTNERSHIP;

SAHARA;

AFRICA SOUTH OF THE SAHARA; BIOMEDICAL TECHNOLOGY; COMMERCE; DIFFUSION OF INNOVATION; HUMANS; INVESTMENTS; MARKETING; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; WORLD HEALTH;

EID: 78650123978     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1195401     Document Type: Review

References (23)

1. A. S. Daar, E. M. Scrimgeour, in Oxford Textbook of Surgery, P. J. Morris and W. C. Wood, Eds. (Oxford Univ. Press, Oxford, 2000), pp. 3278-3292.
2. P. J. Hotez, A. Fenwick, PLoS Negl. Trop. Dis. 3, e485 (2009).
3. Z. A. Andrade, Parasite Immunol. 31, 656 (2009).
4. K. M. Bosompem, O. Owusu, E. O. Okanla, S. Kojima, Trop. Med. Int. Health 9, 991 (2004).
5. J. Gans, S. Stern, Res. Policy 32, 333 (2003).
6. South Africa was excluded from this study because it is classified as an emerging economy with regard to science and technology, and its inclusion would have skewed the findings. Kenya, which has the highest rate of patenting in all of Africa (outside South Africa), and Nigeria, sub-Saharan's largest economy, were chosen because of their relatively well developed innovative sectors, including excellent scientific research institutions and financial sectors. Ghana, Tanzania, and Uganda were chosen because they represent middle-level African countries in this respect; Rwanda was chosen as a representative of the least-developed countries in both the innovative sector and scientific institutions. Northern African countries were excluded because they are not classified as part of sub-Saharan Africa (22).
7. B. Oyelaran-Oyeyinka, paper presented at Innovation in the African Context: A Forum for Policymakers, 6 to 8 March 2007, Dublin, Ireland.
8. F. C. Mills-Robertson et al., Pharm. Pharmacol. 3, 476 (2009).
9. P. A. Singer et al., Nature 449, 160 (2007).
10. P. Wamboga-Mugirya, SciDevNet News, 1 June 2006; www.scidev.net/en/news/ us30m-millennium-science-initiative-for-uganda.html.
11. K. Chege, SciDevNet News, 20 June 2007; www.scidev.net/en/news/kenya- kick-starts-innovation-fund.html.
12. African Union commits to science in Addis Ababa Declaration, www.unesco.org/science/psd/thm-innov/addis-en.shtml.
13. J. E. Aubert, Promoting Innovation in Developing Countries: A Conceptual Framework (World Bank, Washington, DC, 2005).
14. S. E. Frew et al., Nat. Biotechnol. 25, 403 (2007).
15. S. E. Frew et al., Nat. Biotechnol. 26, 37 (2008).
16. R. Rezaie et al., Nat. Biotechnol. 26, 627 (2008).
17. C. Scott, Nat. Med. 13, 228 (2007).
18. S. Nwaka et al., PLoS Med. 7, e1000293 (2010).
19. P. J. Hotez, A. S. Brown, Biologicals 37, 160 (2009).
20. P. Singer et al., in Global Forum Update on Research for Health, vol. 5, Fostering Innovation for Global Health (Global Forum for Health, Geneva, 2008), pp. 143-150.
21. H. Masum, A. S. Daar, S. Al-Bader, R. Shah, P. A. Singer, Innovations 2, 129 (2007).
22. World Economic Forum (WEF), Assessing Africa's Competitiveness in a Global Context (WEF, Geneva, 2007), chap. 1.1, pp. 3-7; www.weforum.org/pdf/gcr/ africa/1.1.pdf.
23. This study was funded by grants from Genome Canada, Ontario Research Fund, Canadian Institutes of Health Research, and the Bill & Melinda Gates Foundation. P.A.S. is chief executive officer, Grand Challenges Canada; a paid adviser to BioVeda China and formerly a paid adviser to Merck Frosst; and a consultant to PepsiCo, Inc. The authors thank J. Clark for editorial comments.